The National Institute of Aging and Alzheimer’s Association (NIAAA)
have recently proposed a common research framework to help
investigators establish a research agenda and evaluate the impact
of various therapeutics in the Alzheimer’s disease (AD) continuum.
Henry J. Riordan and Natalia E. Drosopoulou at Worldwide Clinical
Trials discuss the importance of biomarkers that help to define the
condition of the disease and to track the progression and treatment
effects of AD drugs.